This week, GlaxoSmithKline (GSK) announced that it is implementing contract pharmacy restrictions under 340B. Fortunately, (and despite the somewhat confusing wording in the announcement) all FQHCs and other Federal “grantees” are exempted from these rules. GSK marks the 14th drug maker to implement 340B contract pharmacy restrictions and the 10th to explicitly exempt Federal “grantees” (which includes both FQHC grantees and look-alikes). Notably, GSK has informed hospitals that they can avoid the contract pharmacy restrictions if they provide data about their 340B drugs to the 340BESP website.
